bisindolylmaleimide iv has been researched along with genistein in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchdunger, E; Furet, P; Kump, W; Lydon, N; Mett, H; Meyer, T; Müller, M; Regenass, U; Rihs, G; Trinks, U | 1 |
| Bullock, AN; Debreczeni, JE; Fedorov, OY; Knapp, S; Marsden, BD; Nelson, A | 1 |
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
4 other study(ies) available for bisindolylmaleimide iv and genistein
| Article | Year |
|---|---|
Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding, Competitive; Cells, Cultured; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Phosphorylation; Phthalimides; Proto-Oncogene Proteins c-fos; RNA, Messenger; Structure-Activity Relationship; Tumor Cells, Cultured; Tyrosine | 1994 |
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
Topics: Antineoplastic Agents; Crystallization; Crystallography, X-Ray; Flavonoids; Humans; Imidazoles; Indoles; Maleimides; Models, Molecular; Molecular Structure; Moloney murine leukemia virus; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-pim-1; Proviruses; Pyrazoles; Pyridazines; Pyrimidines; Structure-Activity Relationship | 2005 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |